Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease

Area of Science:

• Biochemistry
• Genetics
• Gene Therapy

Background:

• Severe carbamoyl-phosphate synthetase 1 deficiency is a rare metabolic disorder with high infant mortality.
• Current treatments are limited and often insufficient to manage the condition effectively.

Purpose of the Study:

• To develop and evaluate a customized base-editing therapy for a neonate diagnosed with severe carbamoyl-phosphate synthetase 1 deficiency.
• To assess the safety and preliminary efficacy of lipid nanoparticle-delivered base editing in an infant patient.

Main Methods:

• Development of a tailored base-editing therapy delivered via lipid nanoparticles.
• Administration of two therapeutic infusions to the patient at 7 and 8 months of age under regulatory approval.
• Monitoring of clinical outcomes, including dietary protein intake, medication dosage, and adverse events.

Main Results:

• The patient tolerated the base-editing therapy without unacceptable adverse events, including during viral illnesses.
• Following treatment, the patient could tolerate increased dietary protein and reduced nitrogen-scavenger medication by 50%.
• No serious adverse events were reported during the 7-week follow-up period.

Conclusions:

• Lipid nanoparticle-delivered base editing shows promise as a potential therapeutic strategy for severe carbamoyl-phosphate synthetase 1 deficiency.
• The therapy demonstrated preliminary safety and efficacy in a single infant patient.
• Longer-term follow-up is necessary to fully evaluate the sustained safety and efficacy of this gene-editing approach.